Action Renovacor - RCOR

Outils de qualité professionnelle, pour des investisseurs individuels.

Premium

Dernier

3,20

Prix Achat

Prix Vente

Volume échangé

0,00 Fourchette du Jour 0,00

0,00 Plage de 52 semaines 0,00

Clôture Veille

3,20

Ouverture

Dernière Transaction

Dernière heure de transaction

Volume moyen (3 m)

Volume financier

VWAP

Renovacor Announces Upcoming Presentation at the 29th European Society of Gene & Cell Therapy Congress

Renovacor, Inc. (NYSE: RCOR), a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and...

Renovacor Announces Upcoming Presentation at Keystone Symposia’s Heart Failure: Mechanisms and Therapies Conference

Renovacor, Inc. (NYSE: RCOR), a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and...

Rocket Pharmaceuticals to Acquire Renovacor, Extending Leadership in AAV-based Cardiac Gene Therapy

Acquisition further strengthens Rocket’s leadership in AAV-based cardiac gene therapy and expands Company’s near-term clinical assets for the...

Renovacor Reports Second Quarter 2022 Financial Results and Provides Corporate Update

REN-001 IND submission planned for the second half of 2022 Data from pilot pig study showing successful cardiac transduction with REN-001...

Renovacor Announces Pipeline Expansion with New Research Program for Multiple Genetic Segments of Arrhythmogenic Cardiomyopathy

Research collaboration with the University of Utah's Nora Eccles Harrison Cardiovascular Research and Training Institute expands pipeline with...

Renovacor Announces Data from Pilot Pig Study Showing Successful Cardiac Transduction with REN-001 Delivered Via Low-Dose Retrograde Coronary Sinus Infusion Published in Journal of the American College of Cardiology: Basic to Translational Research

REN-001 delivered locally via low-dose retrograde coronary sinus infusion demonstrated robust, diffuse cardiomyocyte transduction in a large...

Renovacor Reports First Quarter 2022 Financial Results and Provides Corporate Update

REN-001 advancing toward IND submission in the second half of 2022 with the initiation of a Phase I/II clinical trial in BAG3-DCM expected...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

RCOR - Frequently Asked Questions (FAQ)

What is the current Renovacor share price?

The current share price of Renovacor is US$ 3,20

What is the 1 year trading range for Renovacor share price?

Renovacor has traded in the range of US$ 0,00 to US$ 0,00 during the past year

Volume
% Gagnants
% Perdants

Symbole	Prix	Vol.
ATCHAtlasClear Holdings Inc	US$ 2,52 (81,29%)	9,75M
ESPEspey Manufacturing and Electronics Corp	US$ 29,00 (11,54%)	421
PTNPalatin Technologies Inc New	US$ 0,8738 (11,31%)	171
SBITProshares Ultrashort Bitcoin ETF	US$ 13,91 (11,19%)	589,67k
MSTZT Rex 2X Inverse MSTR Daily Target ETF	US$ 20,48 (10,70%)	1,58M
DITAMCON Distributing Co	US$ 100,01 (-25,64%)	1
MLSSMilestone Scientific Inc	US$ 0,923 (-15,32%)	100
ROBNT Rex 2X Long HOOD Daily Target ETF	US$ 14,01 (-13,20%)	5,92k
BITUProshares Ultra Bitcoin ETF	US$ 34,20 (-11,03%)	439,12k
BTCLT Rex 2X Long Bitcoin Daily Target ETF	US$ 35,18 (-10,98%)	3,19k
ATCHAtlasClear Holdings Inc	US$ 2,52 (81,29%)	9,75M
BILSPDR Bloomberg 1 to3 Month T Bill ETF	US$ 91,52 (0,01%)	5,67M
MSTUT Rex 2X Long MSTR Daily Target ETF	US$ 5,43 (-10,69%)	4,31M
ETHU2x Ether ETF	US$ 2,54 (-6,62%)	2,69M
SOXLDirexion Daily Semiconductor Bull 3X Shares	US$ 19,77 (-5,32%)	2M

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Renovacor Inc (RCOR)

Outils de qualité professionnelle, pour des investisseurs individuels.

Statistiques et détails clés

RCOR Dernières nouvelles

Renovacor Announces Upcoming Presentation at the 29th European Society of Gene & Cell Therapy Congress

Renovacor Announces Upcoming Presentation at Keystone Symposia’s Heart Failure: Mechanisms and Therapies Conference

Rocket Pharmaceuticals to Acquire Renovacor, Extending Leadership in AAV-based Cardiac Gene Therapy

Renovacor Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Renovacor Announces Pipeline Expansion with New Research Program for Multiple Genetic Segments of Arrhythmogenic Cardiomyopathy

Renovacor Announces Data from Pilot Pig Study Showing Successful Cardiac Transduction with REN-001 Delivered Via Low-Dose Retrograde Coronary Sinus Infusion Published in Journal of the American College of Cardiology: Basic to Translational Research

Renovacor Reports First Quarter 2022 Financial Results and Provides Corporate Update

RCOR - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Renovacor Inc (RCOR) Cours

Renovacor Inc (RCOR)

Outils de qualité professionnelle, pour des investisseurs individuels.

Statistiques et détails clés

RCOR Dernières nouvelles

Renovacor Announces Upcoming Presentation at the 29th European Society of Gene & Cell Therapy Congress

Renovacor Announces Upcoming Presentation at Keystone Symposia’s Heart Failure: Mechanisms and Therapies Conference

Rocket Pharmaceuticals to Acquire Renovacor, Extending Leadership in AAV-based Cardiac Gene Therapy

Renovacor Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Renovacor Announces Pipeline Expansion with New Research Program for Multiple Genetic Segments of Arrhythmogenic Cardiomyopathy

Renovacor Announces Data from Pilot Pig Study Showing Successful Cardiac Transduction with REN-001 Delivered Via Low-Dose Retrograde Coronary Sinus Infusion Published in Journal of the American College of Cardiology: Basic to Translational Research

Renovacor Reports First Quarter 2022 Financial Results and Provides Corporate Update

RCOR - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS